Peringatan Keamanan

There is limited data on the overdose of dupilumab. As there is no specific treatment for dupilumab, close monitoring of the patient with appropriate symptomatic treatment is advised in case of suspected overdosage.

Dupilumab

DB12159

biotech approved investigational

Deskripsi

Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways.A180478 As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reactions in several atopic or allergic conditions, such as eczema, allergic reaction, and rhinosinusitis.A180478 Dupilumab was generated by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture.L7186

Dupilumab is commonly marketed as Dupixent, which is available as a formulation for subcutaneous injection. It was first approved by the FDA in 2017. It is currently used to treat atopic dermatitis, asthma as an add-on maintenance treatment, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.L41900 It is used as monotherapy or in combination with other drugs, such as corticosteroids.L7186,L7192,L41439 Dupilumab is currently under investigations for potential therapeutic use in diseases driven by allergic reactions or type 2 inflammation, such as pediatric atopic dermatitis, and chronic obstructive pulmonary disease. It is also being studied in combination with another antibody that which targets IL-33.L7225

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) There is limited human data on the half-life of dupilumab.[L7192] In single-dose pharmacokinetic studies, the mean half-life of dupilumab following intravenous or subcutaneous administration ranged from 4.8 to 7 days in rats and 11.7 to 20.5 days in cynomolgus monkeys.[L7369,L7372] In these studies, the mean half-life was comparable was comparable following intravenous and subcutaneous administration.[L7369]
Volume Distribusi The estimated volume of distribution is 4.8 ± 1.3 L.[A180478]
Klirens (Clearance) There is limited data on the clearance of dupilumab.[L7192]

Absorpsi

The Cmax following administration of a single subcutaneous dose of 600 mg or 400 mg of dupilumab were 70.1 ± 24.1 mcg/mL or 41.8 ± 12.4 mcg/mL, respectively. The Tmax ranged from 3 to 7 days following administration of a single subcutaneous dose ranging from 75 to 600 mg.L7186 Following a subcutaneous dose, the absolute bioavailability of dupilumab ranged between 61% and 64% in patients with atopic dermatitis or asthma.L7192 In clinical trials, the steady-state concentrations were reached by week 16 following the administration of 600 mg starting dose and 300 mg dose every other week. At these concentrations, the mean trough concentrations ranged from 60.3 ± 35.1 mcg/mL to 79.9 ± 41.4 mcg/mL for 300 mg dose and from 29.2 ± 18.7 to 36.5 ± 22.2 mcg/mL for 200 mg dose administered every other week.L7186

Metabolisme

Being a monoclonal antibody, dupilumab is not expected to undergo significant hepatic metabolism.L7192 While the metabolism of dupilumab has not been characterized, it is speculated that dupilumab undergoes nonspecific degradation into smaller peptides and amino acids, as often observed with endogenous IgG.A180478

Rute Eliminasi

Being a monoclonal antibody, dupilumab is not expected to undergo significant renal elimination. It is proposed that dupilumab is eliminated via parallel linear and nonlinear pathways. At higher concentrations, dupilumab is primarily cleared through a non-saturable proteolytic pathway. At lower concentrations, it undergoes a non-linear saturable IL-4R ? target-mediated elimination.L7192

Interaksi Obat

387 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Dupilumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Dupilumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Dupilumab.
Estrone Estrone may increase the thrombogenic activities of Dupilumab.
Estradiol Estradiol may increase the thrombogenic activities of Dupilumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Dupilumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Dupilumab.
Mestranol Mestranol may increase the thrombogenic activities of Dupilumab.
Estriol Estriol may increase the thrombogenic activities of Dupilumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Dupilumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Dupilumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Dupilumab.
Tibolone Tibolone may increase the thrombogenic activities of Dupilumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Dupilumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Dupilumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Dupilumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Dupilumab.
Zeranol Zeranol may increase the thrombogenic activities of Dupilumab.
Equol Equol may increase the thrombogenic activities of Dupilumab.
Promestriene Promestriene may increase the thrombogenic activities of Dupilumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Dupilumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Dupilumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Dupilumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Dupilumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Dupilumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Dupilumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Dupilumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Dupilumab.
Formononetin Formononetin may increase the thrombogenic activities of Dupilumab.
Estetrol Estetrol may increase the thrombogenic activities of Dupilumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Dupilumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Dupilumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Dupilumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Dupilumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Dupilumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dupilumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Dupilumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Dupilumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Dupilumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Dupilumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Dupilumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Dupilumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Dupilumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dupilumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Dupilumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dupilumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Dupilumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Dupilumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dupilumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Dupilumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Dupilumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Dupilumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Dupilumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Dupilumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Dupilumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Dupilumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Dupilumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Dupilumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Dupilumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Dupilumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Dupilumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Dupilumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Dupilumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Dupilumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Dupilumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Dupilumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Dupilumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Dupilumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Dupilumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Dupilumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Dupilumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Dupilumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Dupilumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Dupilumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Dupilumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Dupilumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Dupilumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Dupilumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Dupilumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Dupilumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Dupilumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Dupilumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Dupilumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Dupilumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Dupilumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Dupilumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Dupilumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Dupilumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Dupilumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Dupilumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Dupilumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Dupilumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Dupilumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Dupilumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Dupilumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Dupilumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Dupilumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Dupilumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Dupilumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Dupilumab.

Target Protein

Interleukin-4 receptor subunit alpha IL4R
Interleukin-13 IL13
Interleukin-4 IL4

Referensi & Sumber

Artikel (PubMed)
  • PMID: 23688323
    Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B, Hamilton J, Ming JE, Radin A, Stahl N, Yancopoulos GD, Graham N, Pirozzi G: Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66. doi: 10.1056/NEJMoa1304048. Epub 2013 May 21.
  • PMID: 30027349
    Frampton JE, Blair HA: Dupilumab: A Review in Moderate-to-Severe Atopic Dermatitis. Am J Clin Dermatol. 2018 Aug;19(4):617-624. doi: 10.1007/s40257-018-0370-9.
  • PMID: 30186024
    D'Ippolito D, Pisano M: Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis. P T. 2018 Sep;43(9):532-535.
  • PMID: 29939132
    Sastre J, Davila I: Dupilumab: A New Paradigm for the Treatment of Allergic Diseases. J Investig Allergol Clin Immunol. 2018 Jun;28(3):139-150. doi: 10.18176/jiaci.0254.
  • PMID: 29498038
    Davis JD, Bansal A, Hassman D, Akinlade B, Li M, Li Z, Swanson B, Hamilton JD, DiCioccio AT: Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab. Clin Pharmacol Ther. 2018 Dec;104(6):1146-1154. doi: 10.1002/cpt.1058. Epub 2018 Apr 2.
  • PMID: 29176972
    Hurdayal R, Brombacher F: Interleukin-4 Receptor Alpha: From Innate to Adaptive Immunity in Murine Models of Cutaneous Leishmaniasis. Front Immunol. 2017 Nov 10;8:1354. doi: 10.3389/fimmu.2017.01354. eCollection 2017.

Contoh Produk & Brand

Produk: 39 • International brands: 0
Produk
  • Dupixent
    Solution • 100 mg / 0.67 mL • Subcutaneous • Canada • Approved
  • Dupixent
    Solution • 200 mg / 1.14 mL • Subcutaneous • Canada • Approved
  • Dupixent
    Solution • 300 mg / 2 mL • Subcutaneous • Canada • Approved
  • Dupixent
    Injection, solution • 300 mg/2mL • Subcutaneous • US • Approved
  • Dupixent
    Injection, solution • 150 mg/ml • Subcutaneous • EU • Approved
  • Dupixent
    Injection, solution • 150 mg/ml • Subcutaneous • EU • Approved
  • Dupixent
    Injection, solution • 150 mg/ml • Subcutaneous • EU • Approved
  • Dupixent
    Injection, solution • 150 mg/ml • Subcutaneous • EU • Approved
Menampilkan 8 dari 39 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul